MDS Pharma Services Strengthens Therapeutic Focus on Respiratory and Metabolic Disorders
Dr. Bernard Tisserand and Dr. Jonny Salyer appointed Executive Medical Directors to provide leadership and expertise for late stage clinical studies
MDS Pharma Services has named two experienced medical professionals to lead its late stage clinical trial management activities related to respiratory ailments and metabolic disorders. Dr. Bernard Tisserand and Dr. Jonny L. Salyer have been named Executive Medical Directors for Respiratory Disorders and Metabolic Disorders, respectively. These therapeutic areas represent serious global public health concerns and are key areas of focus for MDS Pharma Services' customers.
Respiratory disorders include conditions such as asthma, allergic rhinitis, chronic obstructive pulmonary disease (COPD), and community acquired pneumonia (CAP), while metabolic disorders include diabetes, dyslipidemia, obesity and metabolic syndrome, which is defined as a cluster of conditions that damage the cardiovascular system.
Dr. Tisserand has held a number of senior positions in clinical operations and project management at MDS Pharma Services. In his earlier roles, he managed teams of project directors, project leaders and clinical research associates supporting studies in asthma, allergic rhinitis, COPD, CAP and other major therapeutic areas. He earned his Doctorate in Medicine from René Descartes in Paris and has been with MDS Pharma Services for eighteen years.
Dr. Salyer has nearly 30 years of relevant experience in research, medicine and the contract research industry. Prior to joining MDS, she worked for a leading provider of central laboratory services in Indianapolis, where she served as Director of Medical Affairs since 2001, supporting Phase I-IV clinical research. She earned her Bachelor's Degrees in Chemistry and Microbiology from Indiana University in Bloomington, and her Doctor of Medicine degree from that institution's School of Medicine in Indianapolis.
Other news from the department people
